Results 51 to 60 of about 372,846 (179)
The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective
Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.Increasing evidence indicates an association between type 2 diabetes mellitus and Alzheimer’s disease, contributing to the proposed concept of AD as “type 3 diabetes.” Shared biological features such as impaired insulin signaling, chronic inflammation, mitochondrial dysfunction, and oxidative stress have been observed in both T2DM and AD.
Deniz Catakli +3 more
wiley +1 more source
Sitagliptin and other ‘gliptins’ - why prescribe them? [PDF]
, 2016 Introduction\ud \ud In 2008, the Federal Drug Administration (FDA) required all new glucose-lowering therapies to show cardiovascular safety, and this applies to the dipeptidyl peptidase (DPP)-4 inhibitors (‘gliptins’).
Dimmitt, Simon B., Doggrell, Sheila
core +1 more source
Pakistan Journal of Pharmaceutical SciencesThis study introduces an innovative, and rapid HPLC method using reverse phase elution for the simultaneous analysis of Sitagliptin and Metformin HCl in pharmaceutical formulations.
Mohsin Ali +7 more
doaj +1 more source
Clinics, 2019 OBJECTIVE: To assess the efficacy and safety of sitagliptin compared with voglibose added to combined metformin and insulin in patients with newly diagnosed type 2 diabetes (T2DM).
Chunhong Shi +7 more
doaj +1 more source
Next‐Generation Manufacturing: The Evolving Role of Biocatalysis in AstraZeneca
ChemBioChem, Volume 27, Issue 17, 14 September 2026.Biocatalysis is strengthening AstraZeneca's manufacture of active pharmaceutical ingredients through faster development, robust scale‐up, and lower environmental impact. Case studies illustrate where biocatalysis delivers greatest value, while enabling platforms, teams, and partnerships shape its next phase.
Alba Diaz‐Rodriguez +4 more
wiley +1 more source
Solid-State Characterization of Different Crystalline Forms of Sitagliptin
, 2019 Sitagliptin is an inhibitor of the enzyme dipeptidyl peptidase-4, used for the treatment of type 2 diabetes mellitus. The crystal structure of active pharmaceutical solids determines their physical and chemical properties.
Andressa Veiga +8 more
core +1 more source
Chemistry &Biodiversity, Volume 23, Issue 9, September 2026.Cannabis sativa inflorescence extracts demonstrate promising antidiabetic potential through enzyme inhibition, antioxidant activity, and molecular docking. The hexane extract exhibits the strongest bioactivity, while key cannabinoids show high affinity for diabetes‐related targets, highlighting the plant as a promising source of novel antidiabetic ...
Rosa M. Chinheya +6 more
wiley +1 more source
Formulations and Evaluation of Sitagliptin Phosphate Loaded Transdermal Microspheres Gel [PDF]
, 2018 In this present study was to formulate and evaluate sustained release microsphere gel loaded sitagliptin phosphate in order to maintain a sustained drug concentration in serum for longer period of time, which may result in enhanced absorption and thereby
Vignesh, R
core
Food Science &Nutrition, Volume 14, Issue 9, September 2026.This graphical abstract highlights the versatile therapeutic potential and food applications of Terminalia arjuna, centering on its broad health‐promoting bioactivities. Key mechanisms described include adaptogenic, cardioprotective, gastroprotective, wound‐healing, and anti‐inflammatory effects mediated through Nrf2 and NF‐κB signaling pathways ...
Rameen Naeem +8 more
wiley +1 more source
Formulation and evaluation of sitagliptin phosphate and metformin hydrochloride trilayered tablets [PDF]
, 2013 Sitagliptin phosphate when used alone is an oral anti hyperglycemic drug of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It is available as tablets under trade name JANUVIA.
Chaitanya.N, Prathima Srinivas M
core +2 more sources